Drugs / Tegobuvir
Tegobuvir
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT01225380 | Oct 2010 → Jan 2013 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01072695 | Feb → Oct 2010 | hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00743795 | Oct 2008 → Jul 2009 | hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT01434498 Comparator | Sep 2011 → Jan 2013 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01435226 Comparator | Sep 2011 → Jan 2013 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01353248 Comparator | May 2011 → Oct 2012 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01271790 Comparator | Oct 2010 → Jan 2013 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tegobuvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01353248 ↗ |
| Known as | GS-333126 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1957287 ↗ |
| Known as | GS-9190 | “GS-5885, GS-9451, tegobuvir (GS-9190), and Copegus® for 24 weeks” NCT01434498 ↗ |
| Action | Inhibit | “GS-9190 (non-nucleoside HCV NS5B inhibitor)” NCT01072695 ↗ |
| Modality | Small molecule | — CHEMBL1957287 ↗ |
| Route | Oral | “GS 9190, administered orally twice daily at 40 mg” NCT00743795 ↗ |